Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
238.94
-8.75 (-3.53%)
Sep 17, 2026, 10:55 AM EDT - Market open

Ascendis Pharma Stock Forecast

Stock Price Forecast

According to 20 analysts polled by S&P Global, Ascendis Pharma stock has a consensus rating of "Strong Buy" and an average price target of $312.54. The average 1-year stock price forecast is 30.80% higher than the current stock price, while the lowest is $269.86 (+12.94%) and the highest is $360.06 (+50.69%).

Price Target: $312.54 (+30.80%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$269.86$312.54$314.74$360.06
Change+12.94%+30.80%+31.72%+50.69%

Analyst Ratings

The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingApr '26May '26Jun '26Jul '26Aug '26Sep '26
Strong Buy31314141615
Buy144445
Hold000000
Sell000000
Strong Sell000000
Total41718182020

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$344
BuyReiterates$344+43.97%Sep 16, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
$304
BuyMaintains$304+27.23%Sep 16, 2026
Wedbush
Wedbush
Buy
Maintains
$327
BuyMaintains$327+36.85%Sep 16, 2026
J.P. Morgan
J.P. Morgan
Buy
Maintains
n/a
BuyMaintainsn/an/aSep 15, 2026
BMO Capital
BMO Capital
Buy
Maintains
$319
BuyMaintains$319+33.51%Sep 15, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.37B
from 720.13M
Increased by 89.95%
Revenue Next Year
2.00B
from 1.37B
Increased by 46.36%
EPS This Year
12.75
EPS Next Year
9.59
from 12.75
Decreased by -24.76%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Jan 1, 2023Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
7.78M51.17M266.72M363.64M720.13M1.37B
Revenue Growth
11.87%557.93%421.20%36.34%98.03%89.95%
Gross Profit
4.26M39.04M222.32M319.38M625.22M1.26B
Gross Margin
54.71%76.28%83.36%87.83%86.82%92.28%
Operating Income
-451.79M-561.81M-455.54M-278.76M-136.27M393.28M
Net Income
-383.58M-583.19M-481.45M-378.08M-228.03M963.58M
EPS
-----12.75
Forward PE
-----16.31
Free Cash Flow
-281.90M-156.42M-332.95M-200.32M164.71M481.30M
No. Analysts
-----18
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.

Revenue Forecast

Revenue202620272028
High1.5B
Avg1.4B
Low1.3B

Revenue Growth

Revenue Growth202620272028
High
109.6%
Avg
90.0%
Low
84.4%

EPS Forecast

EPS202620272028
High18.69
Avg12.75
Low3.61

EPS Growth

EPS Growth20272028
High
26.7%
Avg
-24.8%
Low
-50.9%